Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1994702 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $7.49Day +5.94%Mkt cap $430M1Y +99.2%Off 52W high −45.2%Vol (1Y) 102.2%
Daily closing price, split-adjusted to the current basis; 2.4y shown of 615 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.9% of sh out |
| Days to cover6.0d |
| 13F net flow (QoQ)+2.48% |
| Top-10 13F concentration63.0% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$156.4M |
| ROE−64.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−20.3% |
| 1Y+99.2% |
| Since incept. (ann.)−43.0% |
Total return through 2026-07-30 · series begins 2024-02-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)102.2% |
| Ann. volatility (3Y)97.9% |
| Sharpe (1Y)1.17 |
| Sharpe (3Y)−0.09 |
| Max drawdown (1Y)−37.2% |
| Max drawdown (3Y)−93.9% |
| Beta (3Y vs SPY)1.91 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GordonMD Global Investments LP | 4.2M | $37M | 7.02% | −3.3% |
| GILEAD SCIENCES, INC. | 4.1M | $36M | 6.83% | +0.0% |
| Bain Capital Life Sciences Investors, LLC | 3.1M | $27M | 5.15% | +0.0% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.0M | $17M | 3.31% | +0.0% |
| AIGH Capital Management LLC | 2.0M | $17M | 3.31% | +33.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | $15M | 2.95% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6M | $13M | 2.57% | −11.8% |
| Balyasny Asset Management L.P. | 1.1M | $10M | 1.86% | +14.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.66 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$0.85 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.97 | — | — | — |
| 2025-03-31 | 2025-05-13 | −$1.03 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
